Background
The COVID-19 pandemic and the introduction of a state of emergency in many countries around the world have brought to the fore issues of biological safety and the effectiveness of public administration measures.
In his Message to the people of Kazakhstan “The unity of the people and systemic reforms are a solid foundation for the country’s prosperity” dated September 1, 2021, the Head of the State K. Tokayev noted the need to create a national system for forecasting the country’s biological safety and the development of domestic biopharmaceuticals.
In this regard, QazBioPharm National Holding Joint Stock Company was established on December 20, 2021 by the Decree of the Government of the Republic of Kazakhstan with 100% state participation in the authorized capital.
The authorized capital of the Holding was formed through the transfer of the state-owned stake to Scientific Center for Anti-Infectious Drugs JSC. The Ministry of Health of the Republic of Kazakhstan received the right to own and use the state-owned stake of the holding.